NDA to be Submitted for Potential Paroxysmal Nocturnal Hemoglobinuria Treatment
According to a story from globenewswire.com, the biopharmaceutical company Apellis Pharmaceuticals, Inc. has announced that it is currently making plans to submit a New Drug Application (NDA) to the US…